Partner Clyde Tinnen was quoted in the Reorg article, “FIT GOOGL Presidential Transition May Influence US Decision Date,” about whether the Biden administration will continue to support the Trump administration’s antitrust enforcement efforts against Google.
One complication in the United States involves the antitrust enforcement handoff to the Biden camp from the Trump administration, which has not yet conceded the election. “I really don’t know whatto expect, especially given the apparent lack of cooperation of the lame duck administration with thePresident-elect’s team during the transition,” said Tinnen.
(Subscription required.)
One complication in the United States involves the antitrust enforcement handoff to the Biden camp from the Trump administration, which has not yet conceded the election. “I really don’t know whatto expect, especially given the apparent lack of cooperation of the lame duck administration with thePresident-elect’s team during the transition,” said Tinnen.
(Subscription required.)
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”